Kannabis tappaa syöpäsoluja - Cannabis and Cannabinoids (PDQ®)–Patient Version

Nyt se on varmaa! Kannabis tappaa syöpäsoluja

TERVEYS 22.8.2015, 9:30 · ANNIKA KELA

Yhdysvaltain terveysministeriön sivuille on ilmestynyt äskettäin virallinen lausunto, jossa myönnetään, että kannabis tappaa syöpäsoluja. Sama ilmoitus oli julkaistu myös Yhdysvaltain syöpäinstituutin nettisivuilla.

Pitkän tutkimustyön jälkeen Yhdysvallat ovat ilmoittaneet, että kannabiksen käyttäminen auttaa syövästä parantumisessa. Sivustoilla ohjeistetaan syöpäpotilaita käyttämään kannabista polttamalla, syömällä leivosten seassa tai juomalla yrttiteen seassa, sillä kannabinoideista on todettu olevan apua syövän oireisiin ja syöpähoitojen sivuoireisiin.

Sivustolla kerrottiin tutkimuksesta, jossa syöpään sairastuneiden jyrsijöiden syöpä parannettiin kannabiksen avulla. Syöpäsolut kuolivat, kun ne altistuivat kannabiksen vaikutuksille.

Kannabiksen käyttö vähentää potilaiden tulehduksien leviämistä ja ne estävät syöpäsolujen kasvamisen. Kannabiksen käyttöminen estää verisuonten laajenemisen kasvaimien ympärillä ja se estää kasvainta aktivoitumasta.

Joissain tapauksissa kasvaimen toiminta surkastuu ja se alkaa pienentyä.

https://www.stara.fi/2015/08/22/kannabis-tappaa-syopasoluja/

____________________

Cannabis and Cannabinoids (PDQ®)–Patient Version

Questions and Answers About Cannabis

1. What is Cannabis?
   Cannabis , also known as marijuana, is a plant from Central Asia that is grown in many parts of the world today. The Cannabis plant produces a resin containing compounds called cannabinoids. Some cannabinoids are psychoactive (acting on the brain and changing mood or consciousness). In the United States, Cannabisis a controlled substance and has been classified as a Schedule I agent (a drug with a high potential for abuse and no currently accepted medical use).
   Clinical trials that study medicinal Cannabis in cancer are limited. To do research with Cannabis in the United States, researchers must file an Investigational New Drug (IND) application with the Food and Drug Administration (FDA), receive a Schedule I license from the Drug Enforcement Administration (DEA), and gain approval from the National Institute on Drug Abuse (NIDA).
   By federal law, the possession of Cannabis (marijuana) is illegal in the United States outside of approved research settings. However, a growing number of states, territories, and the District of Columbia have enacted laws to legalize medical marijuana. (See Question 4).
2. What are cannabinoids?
   Cannabinoids are active chemicals in Cannabis that cause drug-like effects throughout the body, including the central nervous system and the immune system. They are also known as phytocannabinoids. The main active cannabinoid in Cannabisis delta-9-THC. Another active cannabinoid is cannabidiol (CBD), which may relieve pain and lower inflammation without causing the "high" of delta-9-THC.
   Cannabinoids may be useful in treating the side effects of cancer and cancer treatment.
   Other possible effects of cannabinoids include:
   • Anti-inflammatory activity.
   • Blocking cell growth.
   • Preventing the growth of blood vessels that supply tumors.
   • Antiviral activity.
   • Relieving muscle spasms caused by multiple sclerosis.
3. What is the history of the medical use of Cannabis?
   The use of Cannabis for medicinal purposes dates back at least 3,000 years. It came into use in Western medicine in the 19th century and was said to relieve pain, inflammation, spasms, and convulsions.
   In 1937, the U.S. Treasury began taxing Cannabis under the Marijuana Tax Act at one dollar per ounce for medicinal use and one hundred dollars per ounce for non-medical use. The American Medical Association (AMA) opposed this regulation ofCannabis and did not want studies of its potential medicinal benefits to be limited. In 1942, Cannabis was removed from the U.S. Pharmacopoeia because of continuing concerns about its safety. In 1951, Congress passed the Boggs Act, which includedCannabis with narcotic drugs for the first time.
   Under the Controlled Substances Act passed by Congress in 1970, marijuana was classified as a Schedule I drug. Other Schedule I drugs include heroin, LSD, mescaline, methaqualone, and gamma-hydroxybutyrate (GHB).
   Although Cannabis was not believed to have any medicinal use, the U.S. government distributed it to patients on a case-by-case basis under the Compassionate UseInvestigational New Drug (IND) program started in 1978. This program was closed to new patients in 1992.
   Researchers have studied how cannabinoids act on the brain and other parts of the body. Cannabinoid receptors (molecules that bind cannabinoids) have been discovered in brain cells and nerve cells in other parts of the body. The presence of cannabinoid receptors on immune system cells suggests that cannabinoids may have a role in immunity.
   Nabiximols (Sativex) is a Cannabis extract that contains delta-9-THC and cannabidiol (CBD). Nabiximols is approved in Canada (under the Notice of Compliance with Conditions) for relief of pain in patients with advanced cancer or multiple sclerosis.
4. If Cannabis is illegal, how do some cancer patients in the United States use it?
   Though federal law prohibits the use of Cannabis, the map below shows the states and territories that have legalized Cannabis for medical purposes. Some other states have legalized only one ingredient in Cannabis, such as cannabidiol (CBD), and these states are not included in the map. Medical marijuana laws vary from state to state.

   ENLARGE

   A map showing the U.S. states and territories that have approved the medical use of Cannabis.
5. How is Cannabis administered?
   Cannabis may be taken by mouth or may be inhaled. When taken by mouth (in baked products or as an herbal tea), the main psychoactive ingredient in Cannabis (delta-9-THC) is processed by the liver, making an additional psychoactive chemical.
   When Cannabis is smoked and inhaled, cannabinoids quickly enter the bloodstream. The additional psychoactive chemical is produced in smaller amounts than when taken by mouth.
   A growing number of clinical trials are studying a medicine made from an extract ofCannabis that contains specific amounts of cannabinoids. This medicine is sprayed under the tongue.
6. Have any preclinical (laboratory or animal) studies been conducted usingCannabis or cannabinoids?
   Preclinical studies of cannabinoids have investigated the following:
   Antitumor activity
   • Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory andanimal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells.
   • A study in mice showed that cannabinoids may protect against inflammation of the colon and may have potential in reducing the risk of colon cancer, and possibly in its treatment.
   • A laboratory study of delta-9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9-THC in mouse models of liver cancer showed that it had antitumoreffects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small cell lung cancer cells andbreast cancer cells.
   • A laboratory study of cannabidiol (CBD) in estrogen receptor positive andestrogen receptor negative breast cancer cells showed that it caused cancer cell death while having little effect on normal breast cells. Studies in mouse models of metastatic breast cancer showed that cannabinoids may lessen the growth, number, and spread of tumors.
   • A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC may make chemotherapy such as temozolomide more effective.
   Stimulating appetite
   • Many animal studies have shown that delta-9-THC and other cannabinoids stimulate appetite and can increase food intake.
   Pain relief
   • Cannabinoid receptors (molecules that bind cannabinoids) have been studied in the brain, spinal cord, and nerve endings throughout the body of animals to understand their roles in pain relief.
   • Cannabinoids have been studied for anti-inflammatory effects that may play a role in pain relief.
   • Animal studies have shown that cannabinoids may prevent nerve problems (pain, numbness, tingling, swelling, and muscle weakness) caused by some types of chemotherapy.
   Nausea and vomiting
   • Cannabinoid receptors found in brain cells may have a role in controllingnausea and vomiting. Animal studies have shown that delta-9-THC and other cannabinoids may act on cannabinoid receptors to prevent vomiting caused by certain types of chemotherapy.
   Anxiety and sleep
   • Cannabinoid receptors found in the brain and other parts of the nervous system may be involved in controlling mood and anxiety.
   • Anti-anxiety effects of cannabidiol (CBD) have been shown in several animal models.
7. Have any clinical trials (research studies with people) of Cannabis or cannabinoid use by cancer patients been conducted?
   No clinical trials of Cannabis as a treatment for cancer in humans have been found in the CAM on PubMed database maintained by the National Institutes of Health.
   Cannabis and cannabinoids have been studied in clinical trials for ways to manage side effects of cancer and cancer therapies, including the following:
   Cancer
   • Cannabidiol (CBD) by mouth to treat solid tumors.
   • An oral spray combining 2 cannabinoids (delta-9-THC and CBD) given withtemozolomide to treat recurrent glioblastoma multiforme.
   • Cannabidiol (CBD) to treat acute graft-versus-host disease in patients who have undergone allogeneic hematopoietic stem cell transplantation.
   Nausea and vomiting
   • Delta-9-THC taken by mouth: Two cannabinoid drugs approved in the United States are available under the names dronabinol and nabilone. Both dronabinol and nabilone are approved by the Food and Drug Administration(FDA) for the treatment of chemotherapy-related nausea and vomiting in patients who have not responded to standard therapy. Many clinical trials have shown that both dronabinol and nabilone worked as well as or better than some of the weaker FDA-approved drugs to relieve nausea and vomiting. Newer drugs given for chemotherapy-related nausea have not been directly compared with Cannabis or cannabinoids in cancer patients.
   • Inhaled Cannabis: Ten small trials have studied inhaled Cannabis for the treatment of chemotherapy-related nausea and vomiting. Various study methods and chemotherapy agents were used with mixed results. There is not enough information to interpret these findings.
   • Oral spray with delta-9-THC and cannabidiol (CBD): Nabiximols, a Cannabisextract given as a mouth spray, was shown in a small randomized, placebo-controlled, double-blinded clinical trial in Spain to treat chemotherapy-related nausea and vomiting.
   • There is growing interest in treating children for symptoms such as nausea with Cannabis and cannabinoids, although studies are limited. The American Academy of PediatricsExit Disclaimer has not endorsed Cannabis and cannabinoid use because of concerns about brain development.
   Stimulating appetite
   • Delta-9-THC taken by mouth: A clinical trial compared delta-9-THC (dronabinol) and a standard drug (megestrol) in patients with advanced cancer and loss of appetite. Results showed that delta-9-THC was not as effective in increasing appetite or weight gain in advanced cancer patients compared with standard therapy. However, a clinical trial of patients with HIV/AIDS and weight loss found that those who took delta-9-THC had increased appetite and stopped losing weight compared with patients who took aplacebo.
   • Inhaled Cannabis: There are no published studies of the effect of inhaledCannabis on cancer patients with loss of appetite. Studies of healthy people who inhaled Cannabis showed that they consumed more calories, especially high-fat and sweet snacks.
   Pain relief
   • Combining cannabinoids with opioids: In a small study of 21 patients withchronic pain, combining vaporized Cannabis with morphine relieved pain better than morphine alone, while combining vaporized Cannabis withoxycodone did not produce significantly greater pain relief. These findings should be tested in further studies.
   • Delta-9-THC taken by mouth: Two small clinical trials of oral delta-9-THC showed that it relieved cancer pain. In the first study, patients had good pain relief as well as relief of nausea and vomiting and better appetite. A second study showed that delta-9-THC could be given in doses that gave pain relief comparable to codeine. An observational study of nabilone also showed that it relieved cancer pain along with nausea, anxiety, and distress when compared with no treatment. Neither dronabinol nor nabilone is approved by the FDA for pain management.
   • Cannabis plant extract medicine: A study of an extract of Cannabis that contained specific amounts of cannabinoids, which was sprayed under the tongue, found it was effective in patients with advanced cancer whose pain was not relieved by strong opioids alone. Patients who received the lower doses of cannabinoid spray showed markedly better pain control and less sleep loss compared with patients who received a placebo. Results showed that, for some patients, control of their cancer-related pain continued without needing higher doses of spray or higher doses of their other pain medicines.
   Anxiety and sleep
   • Inhaled Cannabis: A small case series found that patients who inhaled Cannabishad improved mood, improved sense of well-being, and less anxiety.
8. Have any side effects or risks been reported from Cannabis and cannabinoids?
   Adverse side effects of cannabinoids may include:
   • Rapid beating of the heart.
   • Low blood pressure.
   • Muscle relaxation.
   • Bloodshot eyes.
   • Slowed digestion and movement of food by the stomach and intestines.
   • Dizziness.
   • Depression.
   • Hallucinations.
   • Paranoia.
   Because Cannabis smoke contains many of the same substances as tobacco smoke, there are concerns about how inhaled cannabis affects the lungs. A study of over 5,000 men and women without cancer over a period of 20 years found that smoking tobacco was linked with some loss of lung function but that occasional and low use of cannabis was not linked with loss of lung function.
   Because use of Cannabis over a long time may have harmful effects on the endocrineand reproductive systems, rates of testicular germ cell tumors (TGCTs) in Cannabisusers have been studied. Larger studies that follow patients over time and laboratory studies of cannabinoid receptors in TGCTs are needed to find if there is a link between Cannabis use and a higher risk of TGCTs.
   A review of bladder cancer rates in Cannabis users and non-users was done in over 84,000 men who took part in the California Men's Health Study. Over 16 years of follow-up and adjusting for age, race/ethnic group and body mass index (BMI), rates of bladder cancer were found to be 45% lower in Cannabis users than in men who did not report Cannabis use.
   Both Cannabis and cannabinoids may be addictive.
   Symptoms of withdrawal from cannabinoids may include:
   • Irritability.
   • Trouble sleeping.
   • Restlessness.
   • Hot flashes.
   • Nausea and cramping (rarely occur).
   These symptoms are mild compared to withdrawal from opiates and usually lessen after a few days.
9. Are Cannabis or cannabinoids approved by the U.S. Food and Drug Administration for use as a cancer treatment in the United States?
   The U.S. Food and Drug Administration has not approved Cannabis or cannabinoids for use as a cancer treatment.
10. Are Cannabis or cannabinoids approved by the U.S. Food and Drug Administration for use as a treatment for cancer-related symptoms or side effects of cancer therapy?
    Cannabis is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of any cancer-related symptom or side effect of cancer therapy.
    Two cannabinoids (dronabinol and nabilone) are approved by the FDA for the treatment of chemotherapy-related nausea and vomiting in patients who have not responded to standard therapy.
    
    http://www.cancer.gov/about-cancer/treatment/cam/patient/cannabis-pdq/#link/_13

Current Clinical Trials

• Updated: May 27, 2016